| Expression pattern: |
UP |
| Associated gene: |
c-Myc, SPOP |
| Associated microRNA: |
- |
| Biological function: |
CircXPO6 promotes TNBC cell proliferation, migration, clonogenic growth, tumor growth, glucose metabolism, ATP production and glucose uptake. |
| Molecular mechanism: |
CircXPO6 binds c-Myc and competitively inhibits SPOP binding to c-Myc, preventing SPOP-mediated c-Myc ubiquitination and degradation, thereby enhancing c-Myc-mediated glucose metabolism and TNBC progression. |
| Biological pathway or process: |
glycolysis (promotes); proliferation (promotes); migration (promotes); metastasis (promotes); ubiquitination (inhibits); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Microarray; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Co-IP; IHC (Immunohistochemistry); Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; Western Blot; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circXPO6 expression is associated with tumor size, lymph node metastasis, TNM staging, histopathological grading, increased metastasis, and poorer prognosis in TNBC patients. |
| Description: |
CircXPO6 is up-regulated in TNBC tissues and cells and mainly localized in the cytoplasm. It promotes TNBC proliferation, migration, tumor growth and glycolytic metabolism by binding c-Myc and blocking SPOP-mediated c-Myc ubiquitination and degradation. Clinically, high circXPO6 expression is associated with malignant clinicopathological features and poorer prognosis. |
| Confidence score: |
0.8792 |